Neoadjuvant versus adjuvant chemoradiotherapy for resectable cT3‐4a esophageal squamous cell carcinoma: A matched cohort analysis
Mingqiang Lin, Yilin Yu, Yibing Hu, Rong Zheng, Jiancheng Li, Qiwei Yao · 2026
Read Neoadjuvant versus adjuvant chemoradiotherapy for resectable cT3‐4a esophageal squamous cell carcinoma: A matched cohort analysis by Mingqiang Lin, Yilin Yu, Yibing Hu, Rong Zheng, Jiancheng Li, Qiwei Yao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13292158.txt.
Description
Mingqiang Lin and colleagues compare treatment timing for advanced esophageal cancer in a 2026 matched study. Patients had resectable squamous tumors staged cT3 to cT4a. One path gives chemoradiation before surgery, the other after it. Records for 223 patients were balanced into fifty-nine matched pairs by propensity scores. Survival and side effects were then compared head to head.
The before-surgery group lived longer, with median survival near sixty-two months against forty-six. Five-year survival reached about sixty-seven percent against about forty-eight percent. Time without progression also favored the earlier treatment, though its five-year gap missed significance. Side effects looked alike between the paths. Treatment choice, body mass index, and nodal stage each predicted survival. A simple score from weight and nodal stage sorted patients into risk bands, except within the before-surgery group. The authors back chemoradiation first for this stage.
Catalog record
| CREATOR | Mingqiang Lin, Yilin Yu, Yibing Hu, Rong Zheng, Jiancheng Li, Qiwei Yao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |